The invention provides nanoparticle-stabilized nanocapsules, and methods of their preparation and use in delivery of therapeutics, such as nucleic acids. Various embodiments disclosed relate to a nanoparticle-stabilized nanocapsule. Various embodiments disclosed relate to nanoparticle-stabilized nanocapsules for nucleic acid delivery into cells. Various embodiments provide methods of using the nanocapsule for in vivo delivery of the nucleic acid materials.

Hybrid immunoglobulines containing moving parts are provided as well as related compositions and methods of use and methods of production. In addition, analogous genetic devices are provided as well as related compositions and methods of use and methods of production.

Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.

Hybrid immunoglobulins containing moving parts are provided as well as related compositions and methods of use and methods of production. In addition, analogous genetic devices are provided as well as related compositions and methods of use and methods of production.

Disclosed is a stable aqueous pharmaceutical composition or lyophilized pharmaceutical composition comprising a protein as the active ingredient. The pharmaceutical composition comprises a protein having physiological activity and two different nonionic surfactants, including polysorbate 80 and polyoxyethylene(160) polyoxypropylene(30) glycol as the nonionic surfactants, for example, and as optional components, sodium chloride as a neutral salt, sucrose as a disaccharide and citrate buffer as a buffering agent.

Provided herein are immunoconjugate fusion proteins for the treatment of disorders associated with neovascularization (e.g. tumor-associated neovascularization, e.g., ocular melanoma), and symptoms associated with the same. The methods comprise administering the patient in one or more dosing sessions, a composition comprising an effective amount of any one or more of the immunoconjugate proteins described herein, wherein each immunoconjugate comprises at least one mutated Factor VIIa (FVIIa) protein conjugated to an immunoglobulin Ig Fc dimer.

The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.

Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.

The present disclosure relates to compositions and methods for restoring endothelial glycocalyx. Exemplary compositions include nanoparticle compositions of preassembled glycocalyx.

Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-) or interferon beta (IFN-).